This hierarchical relationship between neuropeptide dysregulation and downstream molecular alterations provides critical insights into the pathogenic cascade of CCH and identifies specific neuropeptide signaling pathways as potential high‐priority therapeutic targets for intervention in VCI. The gene discussed is NPS; the disease is columnar cell hyperplasia of the breast.